Digital Health News’ Post

Fortis Healthcare is making a bold move to #acquire a 31% stake in Agilus Diagnostics for ₹1,780 Cr, valuing the company at ₹5,700 Cr! 💰 This #acquisition is part of Fortis’s strategic plan to #strengthen its position in the competitive #diagnostics sector. Agilus, showing strong #financial performance with an 18% EBITDA margin, faces significant #competition but remains a key player. 📊 The deal will be #funded primarily through debt, which may pressure Fortis's margins, but the commitment to #growth is clear.🌍 🔗Read More - https://lnkd.in/dcaZFQnG 🖊️Writes - Dr. Jayati Dubey 🌐Stay Informed with our Latest Stories –  https://lnkd.in/gMUPB2Zp 📌 DHN HealthTech Innovation Challenge 2024 is here, Submit your application today -  https://dhninnovation.com/ #Healthcare #Diagnostics #FortisHealthcare #Investment #India #AgilusDiagnostics #Growth #MergersAndAcquisitions

Leerink Partners, Baird, Barclays, Piper Sandler, RBC Capital Markets, Jefferies: ENOUGH IS ENOUGH! Uncle Rolli Greer & I touched base last night. We discussed the situation again at KPTI and we both are ROYALLY pissed off at the mismanagement of KPTI under current CEO Richard Paulson (who left Ipsen USA without an understanding of 2017 Medicare Part D Plans or LinkedIn's own Multiple Myeloma Hub) and current directors on the board who have been there too long and do NOTHING but rob shareholders like us of equity, cash, and value. FIRE RICHARD PAULSON. I have NO IDEA how he is still CEO. I started buying shares at 69 cents! When he joined the Board of Directors, it was $24! What the hell is going on in Newton, Boston Biotech Advisors, LLC? Richard is mismanaging the company. Richard cancelled the Phase 2 Glioblastoma Multiforme because he is a coward that does not understand current trends in Multiple Myeloma like Uncle Rolli and I do. I have bought shares - starting at 69 cents - and sound more because I have not heard back from Richard. I have not heard back from Elhan Webb, CFA. I have not heard back from the Board like I have Jeff's Brands and Pineapple Energy (Scott Maskin is a LEADER! FOLLOW HIM, not RICHARD!). Here are two visuals side by side. The story has not changed for Karyopharm Commercial in 2 years. I stopped working there in July 2023 and did not make a penny in equity off the company - the shares crashed from $8.90. This is fine. I am more worried for my dear friends and the talent in Karyopharm Medical Affairs. Karyopharm Shareholders like us are pissed off. ROYALLY pissed, sirs. Email me. Or talk to Richard. KPTI's PISS POOR leadership has led to PISS POOR RESULTS. Just like football, and just like all business. Patients are waiting to see if XPOVIO® (selinexor) HCP can Cure Glioblastoma! 1) Fire Richard as CEO. Move Sohanya to CEO or Chief Pipeline Officer 2) Fire the longest tenured Director. I will replace them on the Board or sell my shares and invest in PPBT (Purple Biotech) or RDHL (RedHill Biopharma Ltd.) instead 3) We gotta hire Rolli Greer and Jennifer M. Little-Vito back. It is a PACKAGE DEAL, folks. Otherwise: once Charles Schwab kindly releases my shares to my new brokerage, I will be selling or buying KPTI. You all will hear first. Not Richard. and certainly not Barry or Garen on the incompetent KPTI BOD. ~Jeff Conroy Global HC Analytics LLC Founder & Healthcare Forecasting Lead Email JeffreeNah Jay "Bonesaw" Conroy at: jconroy@theghca.com Source: AAPL Stock App & also KPTI's website https://lnkd.in/ecmSgFiV

JnJ completes acquisition of V Wave  Johnson & Johnson has announced that it has successfully completed the acquisition of V-Wave Ltd., a privately-held company focused on developing innovative treatment options for patients with heart failure. V-Wave will operate as part of Johnson & Johnson MedTech. In accordance with U.S. GAAP, the transaction will be accounted for as an asset acquisition, resulting in an in-process research and development charge of approximately $600 million in the fourth quarter of 2024. As previously disclosed, Johnson & Johnson expects the transaction to dilute adjusted earnings per share (EPS) by approximately $0.24 in 2024 and approximately $0.06 in 2025. Johnson & Johnson will provide an update to its full-year 2024 financial outlook when it reports third quarter 2024 results on October 15, 2024. #johnsonandjohnson #johnsonandjohnsonnews #acquisition #vwave #heartfailure #johnsonandjohnsonmedtech

Edwards Lifesciences has officially completed the sale of its Critical Care business to BD for a staggering $4.2 billion. This change represents a significant move within the industry, impacting both companies and their future directions. Operating as an independent unit within BD's Medical segment, Critical Care will continue its operations from Irvine, California. Katie Szyman, who played a pivotal role at Edwards, will continue to lead the unit. The funds from this sale are earmarked for strategic initiatives at Edwards, including recent acquisitions and share repurchases. Notably, Edwards has been active in the market, recently securing several high-profile acquisitions such as Innovalve Bio Medical Ltd., JenaValve Technology, Inc., and Endotronix. Edwards CEO Bernard Zovighian highlighted the importance of this sale, tying it to the company's focused ambition in structural heart innovation. This shift allows Edwards to hone in on its core areas like TAVR and TMTT while expanding its influence in surgical leadership and new heart therapies. #MedTech #HealthcareInnovation #BusinessGrowth

🚀 J&J's bold medtech vision: is $30B just the beginning? Johnson & Johnson's staggering $30B injection into medtech acquisitions tells us one thing - they're here to play the long game. With impressive Q1 sales of $7.82B showing a steady 4.5% year-on-year growth, J&J's strategic moves are more than just shots in the dark. 💡 The recent acquisition spree including trailblazers like Abiomed, with sales soaring to $371M from $324M last year, shows just how serious J&J is about revolutionizing cardiac care. CEO Joaquin Duato's unwavering commitment to long-term, sector-agnostic M&A pursuits spells an exciting future for industry innovators and the wider public. J&J isn't just thinking growth; they're thinking legacy. 🌱 By eyeing the high-margin, high-impact areas, like cardiovascular tech - where the needs are great and ripe for breakthroughs - they're not only expanding their empire but raising the bar for patient care. It's not just about being a big player; it's about being the right player in the right space at the right time.💼 For those shaping the future at the helm of tech in MedTech, pharma, and BioTech, or those who orchestrate the symphony of executive decision-making - let's talk. This is where foresight meets execution, and where your expertise can become part of a larger narrative. For my fellow HealthTech leaders, how do we see our roles evolving in this transformative era? Drop a comment, let's engage. 💬 #Healthtech #Innovation #JNJ

How does Johnson & Johnson aim to sustain its growth and strategic focus amidst its aggressive acquisitions and changing medtech landscape?   Johnson & Johnson isn't just making waves in the medtech industry; it's orchestrating a symphony of innovation and growth. With Q1 sales surging to a formidable $7.82 billion and cardiovascular sales skyrocketing to $1.81 billion (roughly 20% YoY growth), the numbers speak volumes about J&J's strategic prowess. And let's not forget Abiomed, whose sales jumped to $371 million compared with $324 million in the previous year—a clear indication of momentum.   But what's driving this meteoric rise? One needs only to examine J&J's aggressive acquisition strategy, which has seen the healthcare giant shell out over $30 billion on medtech assets alone in just two years. CEO Joaquin Duato's unwavering commitment to growth underscores the company's long-term vision, with M&A remaining a key priority aimed at driving innovation and enhancing patient care standards.   At the heart of J&J's strategy lies a focused effort on cardiovascular innovation, exemplified by acquisitions like Abiomed and Shockwave Medical. These strategic moves have already paid dividends, with the cardiovascular segment experiencing remarkable growth, particularly in electrophysiology, which saw a staggering 23% year-over-year increase to reach $1.34 billion in sales for the quarter. J&J's pursuit of high-growth markets with groundbreaking technologies sets the stage for even more remarkable feats in the world of medtech.   https://lnkd.in/gX6Di4nv #MedTechNews #MedicalDevices #HealthcareInnovation #MedTechIndustry #HealthTech #HealthcareTechnology #MedDeviceNews #HealthcareNews #MedTechTrends

Quest Diagnostics and Allina Health have announced a significant partnership that will reshape laboratory services in Minnesota and western Wisconsin. Quest Diagnostics has entered into a definitive agreement to acquire select laboratory assets from Allina Health, aiming to enhance access to innovative and cost-effective diagnostic services in the region. This strategic move will allow Quest to expand its extensive service offerings throughout Minnesota and western Wisconsin, providing broader access to their innovative laboratory services for providers and patients. The transaction is expected to be completed in the third quarter of 2024, subject to customary regulatory reviews. Jim Davis, Chairman, CEO and President of Quest Diagnostics, emphasized the shared commitment of both organizations to deliver quality and innovative laboratory services at affordable prices. He stated, "This transaction also reflects progress in delivering on our strategy, which includes generating growth through accretive laboratory acquisitions." Dominica Tallarico,B.S., M.S.,FACHE, Chief Operations Officer for Allina Health, expressed confidence in Quest as the right partner to build upon Allina's foundation of excellence in lab services. She highlighted that this move will allow Allina Health to reinvest its non-profit resources to support its caring mission well into the future. This partnership represents a significant development in the healthcare landscape of the region. https://lnkd.in/e-kSaHiQ 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. You can also access our latest edition here: https://lnkd.in/guUBWkRE #QuestDiagnostics #AllinaHealth #HealthcareInnovation #LaboratoryServices

🌟 𝗧𝗼𝗽 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗗𝗲𝗮𝗹𝘀 𝗼𝗳 𝟮𝟬𝟮𝟰: 𝗔 𝗚𝗮𝗺𝗲-𝗖𝗵𝗮𝗻𝗴𝗲𝗿 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 🌟🔬📣 The first half of 2024 has been monumental for the MedTech industry, with several high-impact deals reshaping the landscape. 🚀🔬 Here are some of the standout transactions: 💰𝗝𝗼𝗵𝗻𝘀𝗼𝗻 & 𝗝𝗼𝗵𝗻𝘀𝗼𝗻'𝘀 $𝟭𝟯.𝟭𝗕 𝗔𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗦𝗵𝗼𝗰𝗸𝘄𝗮𝘃𝗲 𝗠𝗲𝗱𝗶𝗰𝗮𝗹: This deal highlights J&J’s commitment to expanding its cardiovascular portfolio and bringing advanced technologies to market. 💰𝗕𝗼𝘀𝘁𝗼𝗻 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰'𝘀 $𝟯.𝟳𝗕 𝗣𝘂𝗿𝗰𝗵𝗮𝘀𝗲 𝗼𝗳 𝗔𝘅𝗼𝗻𝗶𝗰𝘀: A strategic move to strengthen its position in the neuromodulation space. 💰𝐁𝐃'𝐬 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐒𝐩𝐫𝐞𝐞: BD continues to bolster its portfolio with targeted acquisitions, enhancing its market presence and capabilities. These deals reflect the ongoing innovation and growth within the MedTech sector, driving forward advancements in patient care and medical technology. Johnson & Johnson Boston Scientific BD https://lnkd.in/dAii4vf8 #MedTech #HealthcareInnovation #IndustryNews #JohnsonAndJohnson #BostonScientific #BD #MergersAndAcquisitions

The first half of 2024 saw a series of major #medtech acquisitions, reshaping the industry landscape; leading the pack was Johnson & Johnson's $13.1 billion takeover of Shockwave Medical, among other notable transactions.   1. Johnson & Johnson acquires Shockwave Medical - J&J expands its presence in coronary and peripheral artery disease. J&J expects the acquisition to boost its sales in H2 2024, contributing $77 million in Q2 sales. - Amount: $13.1 billion - Date closed: May 31   2. BD will purchase Edwards Lifesciences' critical care group - BD acquires Edwards’ critical care unit to enhance its business focus. Edwards chose to sell rather than spin off the unit, aiming to concentrate on structural heart innovations. - Amount: $4.2 billion - Date announced: June 3.   3. Boston Scientific to buy Axonics, Inc. - This deal aims to bolster Boston’s urology segment. However, it is pending FTC approval, with closure anticipated in the second half of the year. - Amount: $3.7 billion - Date announced: Jan. 8   4. THL Partners buys Agiliti - THL takes Agiliti private, paying $10 per share. Agiliti, a medical technology services provider, had previously seen its share price fall since its 2021 IPO. - Amount: $2.5 billion - Date closed: May 7   5. Boston Scientific will purchase Silk Road Medical, Inc. - Acquiring Silk Road enhances Boston’s peripheral intervention portfolio. We expect Silk Road's devices for treating carotid artery disease to drive growth in this segment. - Amount: $1.26 billion - Date announced: June 18   These deals highlight the dynamic nature of the medtech sector and the ongoing strategic moves by leading companies to strengthen their market positions and expand their product offerings.   https://lnkd.in/gvQTeaEg #MedTechNews #MedicalDevices #HealthcareInnovation #MedTechIndustry #HealthTech #HealthcareTechnology #MedDeviceNews #HealthcareNews #MedTechTrends

J&J's Strategic Medtech Acquisitions Johnson & Johnson (J&J) is making notable strides in the medtech sector, reflected by a Q3 medtech sales of $7.89 billion, a 5.8% year-over-year increase. The cardiovascular group stood out with over 26% growth, significantly boosted by the acquisitions of Abiomed and Shockwave Medical. These two alone added nearly $2 billion to Q3 sales, with Abiomed contributing $362 million, a 16.3% year-over-year growth. These moves mark J&J's shift towards higher-growth, higher-margin categories. The recent $1.6 billion acquisition of V-Wave supports this strategy, strengthening their cardiovascular portfolio and balancing slower growth in other areas. J&J's CEO, Joaquin Duato, highlighted ongoing innovation efforts like the submission of an investigational device exemption application for the Ottava surgical robot. #MedTech #JohnsonAndJohnson #CardiovascularBusiness